A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

被引:0
作者
A Kotsakis
A Matikas
F Koinis
N Kentepozidis
I I Varthalitis
V Karavassilis
Ep Samantas
P Katsaounis
E K Dermitzaki
D Hatzidaki
D Mavroudis
V Georgoulias
机构
[1] Hellenic Oncology Research Group (HORG),
来源
British Journal of Cancer | 2016年 / 115卷
关键词
NSCLC; cabazitaxel; metastatic; pre-treated; docetaxel; third line;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:784 / 788
页数:4
相关论文
共 417 条
[1]  
Borghaei H(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639
[2]  
Paz-Ares L(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135
[3]  
Horn L(2003)Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats Br J Pharmacol 138 1367-1375
[4]  
Spigel DR(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154
[5]  
Steins M(2009)Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer J Clin Oncol 27 1836-1843
[6]  
Ready NE(2003)Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 3016-3024
[7]  
Chow LQ(2000)Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2354-2362
[8]  
Vokes EE(2013)Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Lancet Oncol 14 981-988
[9]  
Felip E(2014)Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 665-673
[10]  
Holgado E(2007)The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 694-705